Literature DB >> 10869766

Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.

Z Chen1, S Kadowaki, Y Hagiwara, T Yoshikawa, K Matsuo, T Kurata, S Tamura.   

Abstract

Cross-protection against a lethal influenza virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding the neuraminidase (NA) from different subtype A viruses. Each NA-DNA was administered twice, 3 weeks apart, at the dose of 1 microg per mouse by particle-mediated DNA transfer to the epidermis (gene gun) or at a dose of 30 microg per mouse by electroporation into the muscle. Three weeks after the second vaccination, the mice were challenged with lethal doses of homologous or heterologous viruses and the ability of each NA-DNA to protect the mice from influenza was evaluated by determining the lung virus titers, body weight and survival rates. The H3N2 virus NA-DNA conferred cross-protection against lethal challenge with antigenic variants within the same subtype, but failed to provide protection against infection by a different subtype virus (H1N1). The degree of cross-protection against infection was related to titers of the cross-reacting antibodies. These results suggest that NA-DNA can be used as a vaccine component to provide effective protection against infection not only with homologous virus but also with drift viruses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869766     DOI: 10.1016/s0264-410x(00)00149-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Authors:  Glendie Marcelin; Hilliary M Bland; Nicholas J Negovetich; Matthew R Sandbulte; Ali H Ellebedy; Ashley D Webb; Yolanda S Griffin; Jennifer L DeBeauchamp; Janet E McElhaney; Richard J Webby
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

3.  Enhanced growth of seed viruses for H5N1 influenza vaccines.

Authors:  Taisuke Horimoto; Shin Murakami; Yukiko Muramoto; Shinya Yamada; Ken Fujii; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Yoichiro Kino; Yoshihiro Kawaoka
Journal:  Virology       Date:  2007-07-24       Impact factor: 3.616

4.  Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

Authors:  Frédéric Kendirgi; Nadezda E Yun; Nathaniel S Linde; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Harilyn McMicken; Yin Chen; Slobodan Paessler
Journal:  Hum Vaccin       Date:  2008-11-21

5.  Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model.

Authors:  Adrianus C M Boon; Jennifer deBeauchamp; Scott Krauss; Adam Rubrum; Ashley D Webb; Robert G Webster; Janet McElhaney; Richard J Webby
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

6.  Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Authors:  Murugan Subathra; Ponsekaran Santhakumar; Mangamoori Lakshmi Narasu; Syed Sultan Beevi; Sunil K Lal
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

Review 7.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

8.  Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Authors:  Gale E Smith; Xiangjie Sun; Yaohui Bai; Ye V Liu; Michael J Massare; Melissa B Pearce; Jessica A Belser; Taronna R Maines; Hannah M Creager; Gregory M Glenn; David Flyer; Peter Pushko; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

9.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

Review 10.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.